Section Editors

Raffaele Califano - The Christie NHS Foundation Trust, University Hospital of South Manchester NHS Foundation Trust and the University of Manchester, Manchester, UK

Raffaele Califano

The Christie NHS Foundation Trust, University Hospital of South Manchester NHS Foundation Trust and the University of Manchester, Manchester, UK

Dr Raffaele Califano works as Consultant Medical Oncologist at The Christie Hospital and Manchester University Hospital, both in Manchester, United Kingdom. He is also an Honorary Senior Lecturer in Cancer Sciences at The University of Manchester. Dr Califano has a special interest in thoracic malignancies and clinical cancer research and is an active member of the Manchester Lung Cancer Group. Dr Califano graduated in Medicine and Surgery, summa cum laude, from the University of Perugia, Italy in 2003 and completed his Specialist Training in Medical Oncology in 2007. He worked for four years as Clinical Research Fellow with the Lung and Melanoma Team at The Christie Hospital and he has been an investigator for several phase Ib-III clinical trials, developing a particular interest for molecularly-driven clinical trials in advanced non-small cell lung cancer, small cell lung cancer and mesothelioma. Dr Califano has a research focus on immunotherapy and oncogenic-driven lung cancer. Dr Califano serves as Chairman of the European Society of Medical Oncology (ESMO) Publishing Working Group and as a member of the Steering Committee of the ESMO Educational Committee. He is also a member of British Thoracic Oncology Group (BTOG) and International Association for the Study of Lung Cancer (IASLC). Dr Califano is the author of several papers published in indexed, peer-reviewed international journals and he has been an invited speaker to several national and international oncology meetings.

Maurice Pérol - Head of Thoracic Oncology, Medical Oncology Department of Léon Bérard Cancer Center in Lyon.

Maurice Pérol

Head of Thoracic Oncology, Medical Oncology Department of Léon Bérard Cancer Center in Lyon.

Maurice Pérol, M.D., was Associate Professor of Pneumology and Head of the Department of Thoracic Oncology at the Croix-Rousse University Hospital in Lyon, France from 1993 until 2011. He joined in 2011 the Medical Oncology Department of Léon Bérard Cancer Center in Lyon, in which he is responsible for Thoracic Oncology.
His fields of scientific work include clinical phase I, II and III studies in lung cancer, especially in advanced non-small cell lung cancer; this work involves being a principal investigator or key investigator in several French or international cooperative studies. Of note, he was the principal investigator of the IFCT-GFPC 0502 maintenance French study which involves more than 70 centers in France and the co-principal investigator of the international REVEL phase III study assessing ramucirumab in second-line treatment of NSCLC.
He is an active member of many scientific societies, including ASCO, IASLC and ESMO, and collaborative groups. He was the Chairman of the Groupe Français de Pneumo-Cancérologie (GFPC) from 1998 to 2002 and Executive Board member of the French Cooperative Group of Thoracic Oncology "Intergroupe Francophone de Cancérologie Thoracique" (IFCT) from 1999 to 2003; he is member of the IFCT Scientific Board since 2003. He is the author or co-author of more than 140 publications in peer-reviewed journals.

Editor's choice

Oncology & Hematology Review. 2018;14(1):Epub ahead of print.

Latest Articles

Latest Videos

Video List based on Category on Node Page

Latest Videos

Part 2 of 2 - Dr David Heigener discusses the large number of patients that can’t receive targeted therapy or checkpoint inhibitors, and other unmet needs in non-small cell lung cancer (NSCLC). He also gives us his thoughts on liquid biopsy and its use in NSCLC. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Part 1 of 2 – The first part of our interview with Dr David Heigener highlights the lack of data on combination therapies for EGFR-positive non-small cell lung cancer and the issues with synergistic toxicity. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Part 2 of 2 - Dr Maurice Pérol talks to us about the recent IFCT-GFPC 0502-Eco phase III study in optimization of maintenance therapy in non-small cell lung cancer, by tailoring the treatment according to the response from induction chemotherapy. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, US, June 2017

Lung Cancer INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Insight
Durvalumab: first immunotherapy to be approved for stage III non-small cell lung cancer Katrina Mountfort, Medical Writer, Touch Medical Media, Goring-on-Thames, UK